Eli Lilly Shares Surge on Raised Sales Forecast

Eli Lilly raised its full-year sales forecast on continued demand for its obesity and diabetes medications. The company's stock price increased following the announcement. Novo Nordisk, a competitor in the obesity and diabetes drug market, was also discussed in relation to the forecast revision.

• Bloomberg — Eli Lilly Shares Surge on Raised Sales Forecast

Next story